Original language | English |
---|---|
Pages (from-to) | 291-292 |
Number of pages | 2 |
Journal | Diabetic Medicine |
Volume | 34 |
Issue number | 2 |
DOIs | |
State | Published - 1 Feb 2017 |
Externally published | Yes |
Funding
Funders | Funder number |
---|---|
Becton Dickenson | |
Medtronic International Trading Sàrl | |
Eli Lilly and Company | |
Bayer | |
GlaxoSmithKline | |
Sanofi | |
Medtronic | |
Novo Nordisk |
Access to Document
Other files and links
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: Diabetic Medicine, Vol. 34, No. 2, 01.02.2017, p. 291-292.
Research output: Contribution to journal › Letter › peer-review
TY - JOUR
T1 - Factors affecting the benefit of insulin dose intensification in people with Type 2 diabetes
T2 - an analysis from the OpT2mise randomized trial
AU - Schütz-Fuhrmann, I.
AU - Castañeda, J.
AU - Reznik, Y.
AU - Aronson, R.
AU - Conget, I.
AU - Liabat, S.
AU - Runzis, S.
AU - de Portu, S.
AU - Cohen, O.
N1 - Funding Information: I.S-F. reports carrying out clinical trials as co-investigator for Medtronic. Y.R. reports carrying out clinical trials as co-investigator for Medtronic, Eli Lilly and Novo Nordisk, providing advisory services to Medtronic, Abbott and Eli Lilly, attending conferences organized by Eli Lilly and Medtronic as a contributor, and receiving investigator's fees in relation to the OpT2mise protocol; I.C. reports receiving lecturing and consulting fees from Medtronic, Bayer, GSK, Eli Lilly, Novo Nordisk, Sanofi-Aventis, Novartis and MSD, and receiving investigator's fees in relation to the OpT2mise protocol; R.A. reports receiving speaker and consulting fees from Eli Lilly, Novo Nordisk, Sanofi, Becton Dickenson and Medtronic, and receiving investigator's fees in relation to the OpT2mise protocol; O.C. reports carrying out clinical trials as co-investigator for Medtronic, Eli Lilly, Novo Nordisk and Sanofi, providing advisory services and lectures to Medtronic, Eli Lilly and Sanofi, and receiving investigator's fees in relation to the OpT2mise protocol. S.L., S.R., J.C. and S.d.P. are full-time Medtronic employees. Funding for the OpT2mise study was provided by Medtronic International Trading Sàrl, Tolochenaz, Switzerland. Editorial support in the preparation of this letter, funded by Medtronic, was provided by Dr Michael Shaw (MScript Ltd, Hove, UK).
PY - 2017/2/1
Y1 - 2017/2/1
UR - http://www.scopus.com/inward/record.url?scp=85009402286&partnerID=8YFLogxK
U2 - 10.1111/dme.13279
DO - 10.1111/dme.13279
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.letter???
C2 - 27770589
AN - SCOPUS:85009402286
SN - 0742-3071
VL - 34
SP - 291
EP - 292
JO - Diabetic Medicine
JF - Diabetic Medicine
IS - 2
ER -